Other · Acts on phosphatidylserine · developed by Bexion Pharmaceuticals
Phase 1/2Most advanced trial
1Registered trials
What is BXQ-350?
BXQ-350 is a nanovesicle formulation of synthetic saposin C linked to the phospholipid DOPS. It accumulates in tumor vessels and cells, where saposin C fuses with membranes and activates lysosomal enzymes, raising intracellular ceramide and inducing apoptosis. It is being studied in metastatic colorectal carcinoma and neuropathy.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.